Principal Investigator
Marijo Bilusic
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20250919
Clinical Trial Summary
Phase 1, Dose-Escalation Study of KTX-2001 (an NSD2 Inhibitor)
Alone and in Combination with Darolutamide for Metastatic
Castration-Resistant Prostate Cancer
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Prostate, Bladder, and Kidney Cancers
Contact Information
Phone Number
+1 (407) 7659589